Use of corticosteroids in the treatment of patients with diabetic macular edema who have a suboptimal response to anti-VEGF: Recommendations of an expert panel

Carl D. Regillo, David G. Callanan, Diana V. Do, Howard F. Fine, Nancy M. Holekamp, Baruch D. Kuppermann, Michael A. Singer, Rishi P. Singh

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Background and Objective: Guidance on the use of corticosteroids in the treatment of diabetic macular edema (DME) is lacking. This study aimed to develop a clinically recommended treatment paradigm for DME with emphasis on the role of corticosteroids. Patients and Methods: An expert panel of nine retinal specialists in the United States developed consensus recommendations for DME treatment through a modified Delphi process. Results: The panelists typically use intravitreal injections of vascular endothelial growth factor (VEGF) antagonists as first-line treatment of DME and switch patients with an inadequate response to anti-VEGF therapy (failure of best-corrected visual acuity to improve to 20/40 or better because of edema after three to six monthly injections, or a less-than-50% reduction in excess macular thickness after three to four monthly injections) to intra-vitreal corticosteroid treatment. Conclusion: Intravitreal corticosteroids have a potentially useful role in the treatment of patients with DME who have an inadequate response to intravitreal anti- VEGF therapy.

Original languageEnglish
Pages (from-to)291-301
Number of pages11
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume48
Issue number4
DOIs
StatePublished - Apr 2017
Externally publishedYes

Fingerprint

Dive into the research topics of 'Use of corticosteroids in the treatment of patients with diabetic macular edema who have a suboptimal response to anti-VEGF: Recommendations of an expert panel'. Together they form a unique fingerprint.

Cite this